Showing results (51-60 of 206) with videos related to

Sort By:
Pageof 21
Virology|May 29, 2004
Isolation and characterization of subgenomic DNAs encapsidated in "single" T = 1 isometric particles of Maize streak virusCarolina G Casado, G Javier Ortiz, Eric Padron, et al.
Scientific Reports|January 26, 2019
Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemiaBrent M Kuenzi, Lily L Remsing Rix, Fumi Kinose, et al.
American Journal of Hematology|November 4, 2018
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patientsAndrew T Kuykendall, Chetasi Talati, Eric Padron, et al.
Comparative Medicine|July 28, 2019
Effects of Corynebacterium bovis on Engraftment of Patient-derived Chronic-Myelomonocytic Leukemia Cells in NSGS MiceAlexis R Vedder, Emily L Miedel, Natalie H Ragland, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 23, 2025
Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance ClaimsRami S Komrokji, Dylan Supina, Shyamala Navada, et al.
American Journal of Hematology|April 26, 2014
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromesRami S Komrokji, Eric Padron, Daohai Yu, et al.
Leukemia & Lymphoma|April 21, 2020
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failureVu H Duong, Najla Al Ali, Ling Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 11, 2019
Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical TrialRami S Komrokji, Najla H Al Ali, Eric Padron, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary TaleHanadi Ramadan, Vu H Duong, Najla Al Ali, et al.
Journal of Genetic Counseling|September 16, 2023
Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significanceDarcy K Berry, Nancy Gillis, Eric Padron, et al.
Pageof 21